000162415 001__ 162415
000162415 005__ 20251017144608.0
000162415 0247_ $$2doi$$a10.1186/s12868-025-00963-7
000162415 0248_ $$2sideral$$a144982
000162415 037__ $$aART-2025-144982
000162415 041__ $$aeng
000162415 100__ $$0(orcid)0000-0002-0633-2810$$aAlacreu-Crespo, Adrián$$uUniversidad de Zaragoza
000162415 245__ $$aA pharmacological and brain imaging study of human vasopressin AVP1BR receptor functional polymorphisms
000162415 260__ $$c2025
000162415 5060_ $$aAccess copy available to the general public$$fUnrestricted
000162415 5203_ $$aIn humans, vasopressin AVP1BR receptor (hV1B) plays key roles in hypothalamic–pituitary–adrenal (HPA) axis regulation and social behavior. Three hV1B polymorphisms, rs35369693 (K65N), rs28632197 (R364H) and rs33990840 (G191R), have been related to psychiatric disorders with altered HPA axis function and social behavior. The aim of this study was to explore hV1B pharmacological properties as a function of the polymorphism in transfected cells and the brain functioning in an emotional task in volunteers harboring different AVP1BR polymorphisms. Transfection rate, fluorescent imaging and inositol phosphate (IPs) accumulation were evaluated in HEK293 cells that expressed different hV1B variants: K65/G191/R364 (wild type), G191R, K65N and/or R364H. Brain functional activity was investigated in 35 healthy men with different hV1B variants during an fMRI implicit emotional recognition paradigm. IPs accumulation after arginine vasopressin stimulation was much reduced in cells expressing hV1B K65N and/or R364H, and increased in cells expressing G191R. Basal IPs accumulation, transfection rate, and fluorescent binding to plasma membrane were similar for all polymorphisms. During the anger vs. neutral face visualization task, activation of motor areas, visual areas, frontal sub-gyral area, hippocampus, and putamen was higher in homozygotes for the K65/R364 haplotype than in heterozygotes. Analyses did not include participants with the G191 polymorphism because of its low frequency. Different hV1B polymorphisms could be candidates as biomarkers of psychiatric disorders. Moreover, hV1B may be a pharmacological target if these polymorphisms are considered.
000162415 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttps://creativecommons.org/licenses/by/4.0/deed.es
000162415 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000162415 700__ $$aOlié, Emilie
000162415 700__ $$aManière, Maxime
000162415 700__ $$aDeverdun, Jeremy
000162415 700__ $$aLebars, Emmanuelle
000162415 700__ $$aCorbani, Maithé
000162415 700__ $$aGuillon, Gilles
000162415 700__ $$aCourtet, Philippe
000162415 7102_ $$14009$$2680$$aUniversidad de Zaragoza$$bDpto. Psicología y Sociología$$cÁrea Person.Eval.Trat.Psicoló.
000162415 773__ $$g26 (2025), 42 [11 pp.]$$pBMC Neurosci.$$tBMC NEUROSCIENCE$$x1471-2202
000162415 8564_ $$s1476537$$uhttps://zaguan.unizar.es/record/162415/files/texto_completo.pdf$$yVersión publicada
000162415 8564_ $$s2152762$$uhttps://zaguan.unizar.es/record/162415/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000162415 909CO $$ooai:zaguan.unizar.es:162415$$particulos$$pdriver
000162415 951__ $$a2025-10-17-14:15:58
000162415 980__ $$aARTICLE